Abstract
Background Atrioventricular conduction disturbance occurs in a significant number of patients underwent transcatheter aortic valve replacement (TAVR). However, not all of the cases persistently depend on ventricular pacing.
Objective To study the incidence, predictors, and outcomes of new ventricular pacing dependency (VpDep) after TAVR.
Design Prospective, single-center, cohort trial
Methods The first 130 consecutive transfemoral TAVR cases, except 3 with prior cardiac electronic implantable devices (CIEDs) who depended on ventricular pacing, were analyzed. The endpoints were VpDep at 1 month and all-cause mortality at the end of follow-up in 2021. The effects of variables on VpDep and all-cause mortality were evaluated using multivariate binary logistic regression and Cox-regression analysis, respectively. First degree atrioventricular block (AVB) was considered severe when PR interval > 300 ms.
Results Out of 127 patients in the analysis (mean age 82 years, SD 6.3; 62.2% female sex; 67.7% Balloon-expandable device), 7 patients (5.5%) had implanted with CIEDs before TAVR but not ventricular pacing dependent. The incidence of VpDep at 1 month was 7.9% (n=10) among all patients and 34.5% among patients with CIEDs (n=29). VpDep was likely to occur in patients with pre-existing right bundle branch block (OR 21.38; 95% CI 3.25-139.33; P=.001) and severe 1st degree or Mobitz I AVB (OR 14.79; 95% CI 1.65-132.74; P=.016). After a mean follow-up of 25.8 months (SD 21.2), death from any causes occurred in 18 patients (14.2%). VpDep was not associated with excess mortality.
Conclusion VpDep at 1 month occurred in 7.9% of all patients underwent TAVR. Pre-existing conduction abnormalities were significantly associated with higher risk of VpDep. Mortality was similar between patients with and without VpDep.
Clinical Trial Registration Thai Clinical Trial Registration; Study ID: TCTR20220726005
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
http://www.thaiclinicaltrials.org/show/TCTR20220726005
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Ethics Committee, Faculty of Medicine Ramathibodi Hospital, Mahidol University gave ethical approval for this work. Approval number COA. MURA2021/673.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
